Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
by Zacks Equity Research
For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod
by Zacks Equity Research
Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets
by Zacks Equity Research
Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
by Zacks Equity Research
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
National Vision (EYE) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.
Here's Why You Should Retain Patterson Companies (PDCO) Stock Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.
Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations
by Zacks Equity Research
Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.
Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.
Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.
DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.
Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.
OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.
QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.
BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.
PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.
Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.
Ecolab (ECL) Q1 Earnings & Revenues Beat, Margins Up
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its Q1 sales despite business challenges.
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.
Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.